In Brief

Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.

The Amityville, N.Y., facilities of Hi-Tech Pharmacal Co. Inc. lost power from Oct. 29 to Nov. 1 due to Hurricane Sandy and did not produce or ship any Rx or OTC products during that stretch. Though its facilities were not damaged, Hi-Tech lost four days of sales opportunities for cough/cold/flu OTCs while retail orders for those products surged, CEO David Seltzer said Dec. 6. Employees are working overtime now to catch up and the firm expects to make up the lost sales during its current fiscal third quarter, which ends in January. For the preceding quarter ended Oct. 31, Hi-Tech reported net sales up 1.2% to $57.5 million while net income declined 35.3% to $8.9 million as research and development costs jumped 35.5% to $3.3 million. Hi-Tech’s OTC health care products division recorded second-quarter sales essentially flat at $4.7 million, as discounting for the Nasal Ease brand offset sales of the Sinus Buster product acquired in March.

Meda AB expands its consumer health portfolio with the addition of the MidNite herbal sleep support supplement line in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Compliance

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.

More from Pink Sheet

Opuni Appointed Acting CEO Of Ghana’s FDA As Darko Leaves To Lead African Medicines Agency

 

Kwabena Frimpong-Manso Opuni has been appointed as the new acting CEO of the Ghana Food and Drugs Authority, succeeding Delese Darko, who is now head of the Africa’s pan-continental medicines agency.

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.